Quick Facts
| Property | Value |
|---|---|
| Category | Growth Hormone Secretagogue |
| Risk Level | Moderate |
| Administration | Subcutaneous Injection |
| Typical Frequency | 1–3 Times Daily |
| Estimated Half-Life | Short-Acting Peptide |
| Primary Research Interest | Growth Hormone Release / Recovery / Sleep Support |
This material is provided strictly for educational and informational purposes related to peptide research and growth hormone signaling compounds. Ipamorelin is a biologically active growth hormone secretagogue capable of altering growth hormone and metabolic signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2.5 mL
- Final Concentration: 4.00 mg/mL
At this concentration:
• 200 mcg = 0.050 mL (5.0 units)
• 600 mcg = 0.150 mL (15.0 units)
2. Route of Administration
Ipamorelin is most commonly administered as a subcutaneous injectable growth hormone secretagogue.
- Primary Route: SubQ Injection
- Preferred Timing: Commonly administered in fasted states
- Administration Notes: Frequently researched in conjunction with GHRH analogs and recovery-focused protocols
3. Typical Research Protocols
- Product Strength: 4.00 mg/mL
- Typical Delivered Amount: 200–600 mcg daily
- Frequency: Split between 1–3 doses daily
- Cycle Length: 12–16 weeks on / 4–8 weeks off
- Special Notes: Ipamorelin is commonly discussed as one of the milder and more selective growth hormone secretagogues because it appears to produce less cortisol and prolactin elevation compared to compounds such as GHRP-2, GHRP-6, or Hexarelin. Researchers frequently pair Ipamorelin with CJC-1295 or other GHRH analogs in an attempt to amplify pulsatile growth hormone release while maintaining a comparatively tolerable side-effect profile. Many experimental users prefer administration in fasted states because insulin and elevated blood glucose may interfere with growth hormone signaling. Because effects on sleep, recovery, appetite, and body composition typically develop gradually, conservative dosing and long-term consistency are commonly emphasized.
4. Summary
Ipamorelin is an experimental growth hormone secretagogue researched for its potential effects on pulsatile growth hormone release, recovery enhancement, sleep support, and body composition pathways.
Research interest in Ipamorelin commonly centers around recovery optimization, sleep-quality support, body-composition improvement, and growth hormone signaling enhancement.
5. Mechanism of Action
Ipamorelin functions by selectively stimulating ghrelin receptors involved in pulsatile growth hormone release pathways.
- Growth hormone release signaling
- Selective ghrelin receptor activation
- Recovery signaling support
- Potential sleep-quality enhancement
- Metabolic pathway modulation
- Potential IGF-1 support
Compared to many older GHRP compounds, Ipamorelin is commonly discussed as producing a more selective signaling profile.
6. Potential Benefits
- Potential increase in growth hormone signaling
- Enhanced recovery support
- Possible sleep-quality improvements
- Potential body composition support
- Potential IGF-1 pathway support
- Possible synergistic effects with GHRH analogs
7. Potential Risks / Side Effects
Moderate
- Water retention
- Fatigue
- Numbness or tingling
- Potential insulin sensitivity changes
- Headaches
- Injection site irritation
8. Half-Life
Ipamorelin is commonly discussed as a relatively short-acting peptide requiring repeated administration for sustained pulsatile effects.
Because of its shorter duration, many experimental protocols emphasize multiple daily administrations or pairing with longer-acting GHRH analogs.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Active cancer concerns
- Uncontrolled diabetes
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide compounds
- Use alongside multiple hormone-modulating compounds without supervision
11. Research References
- PubMed
- NIH Publications
- Endocrinology literature
- Peer-reviewed growth hormone and metabolism journals
CKF Tide Tables 